1J74
 
 | | Crystal Structure of Mms2 | | Descriptor: | MMS2 | | Authors: | Moraes, T.F, Edwards, R.A, McKenna, S, Pastushok, L, Xiao, W, Glover, J.N.M, Ellison, M.J. | | Deposit date: | 2001-05-15 | | Release date: | 2001-08-08 | | Last modified: | 2023-08-16 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2-hUbc13.
Nat.Struct.Biol., 8, 2001
|
|
1J7D
 | | Crystal Structure of hMms2-hUbc13 | | Descriptor: | MMS2, UBIQUITIN-CONJUGATING ENZYME E2-17 KDA | | Authors: | Moraes, T.F, Edwards, R.A, McKenna, S, Pashushok, L, Xiao, W, Glover, J.N.M, Ellison, M.J. | | Deposit date: | 2001-05-16 | | Release date: | 2001-08-08 | | Last modified: | 2024-02-07 | | Method: | X-RAY DIFFRACTION (1.85 Å) | | Cite: | Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2-hUbc13.
Nat.Struct.Biol., 8, 2001
|
|
4ONM
 | | Crystal structure of human Mms2/Ubc13 - NSC697923 | | Descriptor: | 2-[(4-methylphenyl)sulfonyl]-5-nitrofuran, GLYCEROL, Ubiquitin-conjugating enzyme E2 N, ... | | Authors: | Hodge, C.D, Edwards, R.A, Glover, J.N.M. | | Deposit date: | 2014-01-28 | | Release date: | 2015-05-06 | | Last modified: | 2017-11-22 | | Method: | X-RAY DIFFRACTION (1.35 Å) | | Cite: | Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting.
Acs Chem.Biol., 10, 2015
|
|
4ONN
 | | Crystal structure of human Mms2/Ubc13 - BAY 11-7082 | | Descriptor: | 3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile, GLYCEROL, Ubiquitin-conjugating enzyme E2 N, ... | | Authors: | Hodge, C.D, Edwards, R.A, Glover, J.N.M. | | Deposit date: | 2014-01-28 | | Release date: | 2015-05-06 | | Last modified: | 2017-11-22 | | Method: | X-RAY DIFFRACTION (1.5 Å) | | Cite: | Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting.
Acs Chem.Biol., 10, 2015
|
|
4OFB
 | |
4ONL
 | | Crystal structure of human Mms2/Ubc13_D81N, R85S, A122V, N123P | | Descriptor: | Ubiquitin-conjugating enzyme E2 N, Ubiquitin-conjugating enzyme E2 variant 2 | | Authors: | Hodge, C.D, Edwards, R.A, Glover, J.N.M. | | Deposit date: | 2014-01-28 | | Release date: | 2015-05-06 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.35 Å) | | Cite: | Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting.
Acs Chem.Biol., 10, 2015
|
|
4ORH
 | | Crystal structure of RNF8 bound to the UBC13/MMS2 heterodimer | | Descriptor: | E3 ubiquitin-protein ligase RNF8, Ubiquitin-conjugating enzyme E2 N, Ubiquitin-conjugating enzyme E2 variant 2, ... | | Authors: | Campbell, S.J, Edwards, R.A, Glover, J.N.M. | | Deposit date: | 2014-02-11 | | Release date: | 2014-02-26 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (4.802 Å) | | Cite: | Molecular insights into the function of RING finger (RNF)-containing proteins hRNF8 and hRNF168 in Ubc13/Mms2-dependent ubiquitylation.
J.Biol.Chem., 287, 2012
|
|
4QPO
 | | Mechanistic basis of plasmid-specific DNA binding of the F plasmid regulatory protein, TraM | | Descriptor: | PHOSPHATE ION, Relaxosome protein TraM | | Authors: | Peng, Y, Lu, J, Wong, J, Edwards, R.A, Frost, L.S, Glover, J.N.M. | | Deposit date: | 2014-06-24 | | Release date: | 2014-09-03 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (1.999 Å) | | Cite: | Mechanistic Basis of Plasmid-Specific DNA Binding of the F Plasmid Regulatory Protein, TraM.
J.Mol.Biol., 426, 2014
|
|
6DCX
 | | iASPP-PP-1c structure and targeting of p53 | | Descriptor: | RelA-associated inhibitor, Serine/threonine-protein phosphatase PP1-alpha catalytic subunit | | Authors: | Glover, J.N.M, Zhou, Y, Edwards, R.A. | | Deposit date: | 2018-05-08 | | Release date: | 2019-05-15 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (3.408 Å) | | Cite: | Flexible Tethering of ASPP Proteins Facilitates PP-1c Catalysis.
Structure, 27, 2019
|
|
6SLG
 | | HUMAN ERK2 WITH ERK1/2 INHIBITOR, AZD0364. | | Descriptor: | (6~{R})-7-[[3,4-bis(fluoranyl)phenyl]methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one, 1,2-ETHANEDIOL, ERK-tide, ... | | Authors: | Breed, J, Phillips, C. | | Deposit date: | 2019-08-19 | | Release date: | 2019-11-20 | | Last modified: | 2024-05-15 | | Method: | X-RAY DIFFRACTION (1.33 Å) | | Cite: | Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
J.Med.Chem., 62, 2019
|
|
4LI5
 | | EGFR-K IN COMPLEX WITH N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-phenyl] Prop-2-enamide | | Descriptor: | Epidermal growth factor receptor, N-(3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-4-methoxyphenyl)propanamide, SODIUM ION | | Authors: | Debreczeni, J.E, Seiffert, G.B, Kiefersauer, R, Augustin, M, Nagel, S, Ward, R, Anderton, M, Ashton, S, Bethel, P, Box, M, Butterworth, S, Colclough, N, Chroley, C, Chuaqui, C, Cross, D, Eberlein, C, Finlay, R, Hill, G, Grist, M, Klinowska, T, Lane, C, Martin, S, Orme, J, Smith, P, Wang, F, Waring, M. | | Deposit date: | 2013-07-02 | | Release date: | 2013-08-28 | | Last modified: | 2024-02-28 | | Method: | X-RAY DIFFRACTION (2.64 Å) | | Cite: | Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR).
J.Med.Chem., 56, 2013
|
|
9EWT
 | | Optimisation of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations | | Descriptor: | 1-[2-[3-[(E)-2-(5-cyclopropyl-1,3-oxazol-2-yl)ethenyl]phenyl]-3-pyridin-4-yl-4,6-dihydropyrrolo[3,4-d]imidazol-5-yl]propan-1-one, Epidermal growth factor receptor | | Authors: | Hargreaves, D. | | Deposit date: | 2024-04-04 | | Release date: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (3.019 Å) | | Cite: | Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations.
J.Med.Chem., 2024
|
|
8PO2
 | |
8PO0
 | |
8PO3
 | |
8PO1
 | |
8PO4
 | |
8PNZ
 | |
7AEM
 | | Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series | | Descriptor: | 5-chloro-N~4~-[2-(dimethylphosphoryl)phenyl]-N~2~-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine, Epidermal growth factor receptor | | Authors: | Hargreaves, D. | | Deposit date: | 2020-09-17 | | Release date: | 2021-04-07 | | Last modified: | 2024-05-01 | | Method: | X-RAY DIFFRACTION (2.65 Å) | | Cite: | Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation
Cancer Res., 79, 2019
|
|
7AEI
 | | Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series | | Descriptor: | 5-chloranyl-~{N}2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-~{N}4-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine, Epidermal growth factor receptor | | Authors: | Hargreaves, D. | | Deposit date: | 2020-09-17 | | Release date: | 2021-06-02 | | Last modified: | 2024-05-01 | | Method: | X-RAY DIFFRACTION (2.65 Å) | | Cite: | Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation
Cancer Res., 79, 2019
|
|
5KBR
 | | Pak1 in complex with 7-azaindole inhibitor | | Descriptor: | (4-chlorophenyl)-[5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridin-3-yl]methanone, Serine/threonine-protein kinase PAK 1 | | Authors: | Ferguson, A. | | Deposit date: | 2016-06-03 | | Release date: | 2016-09-28 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.36 Å) | | Cite: | Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.
ACS Med Chem Lett, 7, 2016
|
|
5KBQ
 | | Pak1 in complex with bis-anilino pyrimidine inhibitor | | Descriptor: | Serine/threonine-protein kinase PAK 1, [4-methyl-3-[methyl-[2-[(3-methylsulfonyl-5-morpholin-4-yl-phenyl)amino]pyrimidin-4-yl]amino]phenyl]methanol | | Authors: | Ferguson, A. | | Deposit date: | 2016-06-03 | | Release date: | 2016-09-28 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2.58 Å) | | Cite: | Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.
ACS Med Chem Lett, 7, 2016
|
|
4P90
 | | Crystal structure of the kinase domain of human PAK1 in complex with compound 15 | | Descriptor: | Serine/threonine-protein kinase PAK 1, [2-chloro-5-(hydroxymethyl)phenyl]{5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}methanone | | Authors: | Ferguson, A.D. | | Deposit date: | 2014-04-01 | | Release date: | 2014-09-10 | | Last modified: | 2023-09-27 | | Method: | X-RAY DIFFRACTION (2.49 Å) | | Cite: | Identification and optimisation of 7-azaindole PAK1 inhibitors with improved potency and kinase selectivity.
MEDCHEMCOMM, 2014
|
|
3L11
 | | Crystal Structure of the Ring Domain of RNF168 | | Descriptor: | E3 ubiquitin-protein ligase RNF168, MALONATE ION, ZINC ION | | Authors: | Neculai, D, Yermekbayeva, L, Crombet, L, Weigelt, J, Bountra, C, Edwards, A.M, Arrowsmith, C.H, Bochkarev, A, Dhe-Paganon, S, Structural Genomics Consortium (SGC) | | Deposit date: | 2009-12-10 | | Release date: | 2010-01-19 | | Last modified: | 2023-09-06 | | Method: | X-RAY DIFFRACTION (2.12 Å) | | Cite: | Molecular insights into the function of RING finger (RNF)-containing proteins hRNF8 and hRNF168 in Ubc13/Mms2-dependent ubiquitylation.
J.Biol.Chem., 287, 2012
|
|
3MW6
 | | Crystal structure of NMB1681 from Neisseria meningitidis MC58, a FinO-like RNA chaperone | | Descriptor: | GLYCEROL, uncharacterized protein NMB1681 | | Authors: | Tan, K, Zhou, M, Duggan, E, Abdullah, J, Joachimiak, A, Midwest Center for Structural Genomics (MCSG) | | Deposit date: | 2010-05-05 | | Release date: | 2010-06-23 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (2.209 Å) | | Cite: | N. meningitidis 1681 is a member of the FinO family of RNA chaperones.
Rna Biol., 7, 2010
|
|
